Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment

Two open‐label studies assessed the safety, tolerability, and pharmacokinetics of Oxbryta (voxelotor) in subjects with hepatic or renal impairment. Eight subjects with severe renal impairment (estimated glomerular filtration rate <30 mL/min/1.73 m(2)) and 8 healthy age‐, sex‐, and body mass index...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Clin Pharmacol
Main Authors: Preston, Richard A., Marbury, Thomas, Balaratnam, Ganesh, Green, Michelle, Dixon, Sandy, Lehrer‐Graiwer, Josh, Washington, Carla
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2020
Teme:
Editor's Choice: Special Populations
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7984382/
https://ncbi.nlm.nih.gov/pubmed/33084052
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1757
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki